Nanoparticle Albumin-Bound-Paclitaxel in the Treatment of Metastatic Urethral Adenocarcinoma: The Significance of Molecular Profiling and Targeted Therapy

<table>The figure shows the dramatic response of metastatic urethral cancer to nanoparticle albumin-bound (nab) paclitaxel. CT scan performed before therapy (a) showed an 11.5 cm metastatic mass in the left pelvis. This mass decreased to 3.5 cm after 5 months of nab-paclitaxel (b).</table>

Case Reports in Urology

fig1

Figure 1

Figure 1: Nanoparticle Albumin-Bound-Paclitaxel in the Treatment of Metastatic Urethral Adenocarcinoma: The Significance of Molecular Profiling and Targeted Therapy 

Figure 1 | Nanoparticle Albumin-Bound-Paclitaxel in the Treatment of Metastatic Urethral Adenocarcinoma: The Significance of Molecular Profiling and Targeted Therapy 